Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First in human study of bispecific PSMAxCD3 antibody CC-1 in castration resistant prostate carcinoma
2024-512894-29-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CC-1 in prostate cancer (PCa), sponsored by University Hospital Tübingen. Primary endpoints: Safety and tolerability of CC-1 and Preliminary antitumor efficacy of CC-1. Planned start Apr 2024; status: authorised.
02
Drugs
CC-1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-512894-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512894-29-00.